ArticlePloS one2012

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

Viktor von Wyl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.